ArticleFrontiers in medicine2026
Toxicokinetics and postmortem redistribution of amantadine in rats.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Amantadine (AMD) is an antiviral and antiparkinsonian drug with a narrow therapeutic window and a recognized risk of severe intoxication. Interpretation of postmortem drug concentrations is complicated by postmortem redistribution (PMR), yet systematic toxicokinetic and multi-tissue PMR data for amantadine remain limited. Methods: An integrated investigation of amantadine toxicokinetics and postmortem redistribution was conducted in male rats. For toxicokinetic assessment, a single oral dose of 450 mg/kg (LD50) was administered, and concentrations were quantified in blood and nine tissues over a 96-h period. For the PMR study, rats received low (42 mg/kg), medium (LD50), and high (2 × LD50) doses, followed by controlled postmortem storage at 4 °C and 20 °C for up to 96 h. Amantadine concentrations were determined using validated HPLC-MS/MS methods and analyzed by pharmacokinetic and statistical approaches. Results: Amantadine was rapidly absorbed and widely distributed, exhibiting pronounced tissue-specific heterogeneity. The liver and kidney showed the highest exposure, whereas accumulation in the brain and testis was limited. Postmortem redistribution was substantial and tissue dependent, and was strongly influenced by dose, postmortem interval, and storage temperature. Blood concentrations were unstable over time, while solid organs, particularly the liver and spleen, exhibited higher and more sustained postmortem concentrations. Notably, selected inter-tissue concentration ratios (e.g., liver-to-lower limb muscle and spleen-to-brain) displayed consistent, dose-dependent trends across postmortem conditions. Conclusions: This study provides a comprehensive characterization of amantadine toxicokinetics and postmortem redistribution across multiple biological matrices. The findings underscore the limitations of relying solely on postmortem blood concentrations and support the complementary use of selected tissues and inter-tissue concentration ratios as comparative indicators in toxicological interpretation. These results offer mechanistic insight into postmortem drug dynamics and provide practical reference data to improve the interpretation of suspected amantadine intoxication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.